Iris Acquisition Corp Edges Closer To Merging With Liminatus Pharma

Iris Acquisition Corp. is advancing its plans to merge with Liminatus Pharma, LLC. In its latest move, the company filed an amended Form S-4 with the Securities and Exchange Commission (SEC) on August 7, 2024, bringing the business combination a step closer to reality. Initially proposed on November 30, 2022, the merger could lead to Liminatus Pharma becoming a publicly traded entity under Iris Parent Holding Corp. The recent SEC filing includes a preliminary proxy statement and prospectus, providing Iris's stockholders with detailed insights into the proposed merger. A definitive proxy statement will be released once the SEC approves the registration.

Iris Acquisition Corp, trading on Nasdaq under various symbols (IRAAU, IRAA, IRAAW), is headquartered in the Cayman Islands. Led by CEO Sumit Mehta, the company is seeking stockholder approval to finalize the merger, which could significantly impact the pharmaceutical industry. In a related development, Iris Acquisition Corp and its PIPE subscriber have mutually agreed to terminate their Convertible Note Subscription Agreement and the associated Convertible Note, further shaping the future of this potential merger. In addition, Iris Acquisition Corp successfully secured an extension for its Nasdaq Capital Market listing. After appealing to the Nasdaq Hearings Panel, the company’s deadline was pushed back to September 3, 2024.